2m 2m 2m 2m 2m 2m 2m
ONKURE THERAP-A (OKUR)
NASDAQ
$4.21+$0.005 (+0.12%)
Price as of Jun 23, 2026 4:35 PM EDT- $179.4MMarket Cap
- 64.06%1-Year Change
- BiotechnologyIndustry
ONKURE THERAP-A (OKUR)
$4.21+$0.005 (+0.12%)
Key Performance
More- Earnings Score: N/A
- Momentum Score: 56
- True Yield: N/A
- Financial Health Score: N/A
Latest Research & News
No data found
Peers
- XLOXILIO THERAP
$9.06+1.34%Market Cap$58.8M1-Year Change-4.69%
Statistics
MoreDay Range
$4.13
$4.55
$4.20
1-Year Range
$2.00
$5.27
$4.20
Latest Close$4.20
Change
-$0.24 (-5.71%)
Volume292,286
Market Cap$179.4M
Shares Outstanding40.4M
P/E (TTM)-1.03
Diluted EPS (TTM)-$4.33
Enterprise Value-$12.8M
Information as of 06/23/2026
Company Profile
ONKURE THERAPEUTICS INC
https://onkuretherapeutics.com$179.4M
Market Cap
-$58.7M
Net Income
Sector: Healthcare
Industry: Biotechnology
6707 Winchester Circle, Boulder, CO, United States, 80301
720-307-2892OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company was founded in 2011 and is headquartered in Boulder, Colorado.
Key Executives
- Nicholas A. Saccomano
- Samuel Agresta
- Jason A. Leverone
- Isaac Manke
- Dylan Hartley
Current Ownership Distribution
- Institutions69.0M (88.90%)
- Insiders7.9M (10.19%)
- Mutual Funds705,680 (0.91%)
- Other0 (0.00%)